Month: November 2025

By a final and binding ruling, the Panevėžys Regional Court decided to terminate the restructuring proceedings initiated on 11 October 2024 and to open bankruptcy proceedings for RUAB “Alinita”, a company belonging to the PST Group AB corporate group. The court appointed UAB “AVERE” as the insolvency administrator and instructed it to organize the first meeting of creditors according to the procedure established by law. The director of RUAB “Alinita”, Juozas Vyšniauskas, stated that despite maximum efforts to implement the restructuring plan and restore solvency, the company was ultimately unable to overcome its financial challenges and return to normal business operations. More information:Tomas Stukas Managing Director Tel.: +370 618 21360

Laurent-Perrier Group        Tours-sur-Marne, 28 November 2025 Financial press releaseResults for the first six months of the 2025-2026 financial year Laurent-Perrier: Revenue up, Net profit slightly lowerand profitability remains high The financial statements for the first half of the 2025-2026 financial year, ended 30 September 2025, were approved by the Management Board at its meeting held on 25 November 2025 and reviewed the same day by the Supervisory Board, chaired by Mr Patrick THOMAS. Key consolidated financial data:In millions of EurosAt 30 September 2025 1st 6 monthsFinancial year2024-2025(1 April 2024 –30 September 2024) 1st 6 monthsFinancial year2025-2026(1 April 2025 –30 September 2025) Change vs FY N-1Champagne sales 128.8 133.3 +3.5%Group revenue 132.0 134 +1.5%Operating profit 38.8 36.6 -5.7%Operating...

Marks the solid execution of FF and FX’s Global Automotive Bridge Strategy in the Middle East, signaling a new phase in the Company’s Middle East Three-Pole strategy and lays a core foundation for future sales. FF and FX will expand Co-Creation initiatives with FX Super One’s first global owner and Developer Co-Creation Officer Andrés Iniesta, accelerating the Middle East’s transition into the new era of EAI-MPV mobility. FX Super One will begin broader deliveries in the UAE, with the goal of becoming the region’s leading MPV.DUBAI, United Arab Emirates, Nov. 27, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“Faraday Future,” “FF,” or “the Company”), a global shared intelligent electric mobility ecosystem company headquartered in California, announced today that the Company hosted a Co-Creation...

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with prurigo nodularis in China. Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are strategically positioned within the vast dermatology market, including atopic dermatitis, vitiligo, prurigo nodularis, urticaria, and more. TYK2 plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases. Prurigo...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for “LEQEMBI®” (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The application is based on data from multiple subcutaneous (SC) administration sub-studies of lecanemab conducted...

TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) — Optiva Inc. (TSX: OPT) (“Optiva“) is pleased to announce that the shareholders of Optiva (the “Shareholders“) and the holders (the “Noteholders“) of principal amount of 9.75% senior secured payment-in-kind toggle notes (“PIK Notes“) have approved the proposed plan of arrangement (the “Arrangement“) involving Qvantel Oy (the “Purchaser“) at the special meeting of Shareholders (the “Shareholder Meeting“) and special meeting of Noteholders (the “Noteholder Meeting” and collectively with the Shareholder Meeting, the “Meetings“) held earlier today. Pursuant to the Arrangement, (i) the Purchaser will acquire all of the issued and outstanding common shares of Optiva (the “Shares“)...